Drug–drug interactions (DDIs) can affect both treatment efficacy and toxicity. We used Drug-PIN® (Personalized Interactions Network) software in colorectal cancer (CRC) patients to evaluate drug–drug–gene interactions (DDGIs), defined as the combination of DDIs and individual genetic polymorphisms. Inclusion criteria were: (i) stage II-IV CRC; (ii) ECOG PS (Performance status sec. Eastern coperative oncology group) ≤2; (iii) ≥5 concomitant drugs; and (iv) adequate renal, hepatic, and bone marrow function. The Drug-PIN® system analyzes interactions between active and/or pro-drug forms by integrating biochemical, demographic, and genomic data from 110 SNPs. We selected DDI, DrugPin1, and DrugPin2 scores, resulting from concomitant medication interactions, concomitant medications, and SNP profiles, and DrugPin1 added to chemotherapy drugs, respectively. Thirty-four patients, taking a median of seven concomitant medications, were included. The median DrugPin1 and DrugPin2 scores were 42.6 and 77.7, respectively. In 13 patients, the DrugPin2 score was two-fold higher than the DrugPin1 score, with 7 (54%) of these patients experiencing severe toxicity that required hospitalization. On chi-squared testing for any toxic-ity, a doubled DrugPin2 score (p = 0.001) was significantly related to G3–G4 toxicity. Drug-PIN® software may prevent severe adverse events, decrease hospitalizations, and improve survival in cancer patients.

Drug–drug interactions and pharmacogenomic evaluation in colorectal cancer patients. The new drug-pin® system comprehensive approach / Roberto, M.; Rossi, A.; Panebianco, M.; Pomes, L. M.; Arrivi, G.; Ierino, D.; Simmaco, M.; Marchetti, P.; Mazzuca, F.. - In: PHARMACEUTICALS. - ISSN 1424-8247. - 14:1(2021), pp. 1-12. [10.3390/ph14010067]

Drug–drug interactions and pharmacogenomic evaluation in colorectal cancer patients. The new drug-pin® system comprehensive approach

Roberto M.;Rossi A.;Panebianco M.
;
Pomes L. M.;Arrivi G.;Simmaco M.;Marchetti P.;Mazzuca F.
2021

Abstract

Drug–drug interactions (DDIs) can affect both treatment efficacy and toxicity. We used Drug-PIN® (Personalized Interactions Network) software in colorectal cancer (CRC) patients to evaluate drug–drug–gene interactions (DDGIs), defined as the combination of DDIs and individual genetic polymorphisms. Inclusion criteria were: (i) stage II-IV CRC; (ii) ECOG PS (Performance status sec. Eastern coperative oncology group) ≤2; (iii) ≥5 concomitant drugs; and (iv) adequate renal, hepatic, and bone marrow function. The Drug-PIN® system analyzes interactions between active and/or pro-drug forms by integrating biochemical, demographic, and genomic data from 110 SNPs. We selected DDI, DrugPin1, and DrugPin2 scores, resulting from concomitant medication interactions, concomitant medications, and SNP profiles, and DrugPin1 added to chemotherapy drugs, respectively. Thirty-four patients, taking a median of seven concomitant medications, were included. The median DrugPin1 and DrugPin2 scores were 42.6 and 77.7, respectively. In 13 patients, the DrugPin2 score was two-fold higher than the DrugPin1 score, with 7 (54%) of these patients experiencing severe toxicity that required hospitalization. On chi-squared testing for any toxic-ity, a doubled DrugPin2 score (p = 0.001) was significantly related to G3–G4 toxicity. Drug-PIN® software may prevent severe adverse events, decrease hospitalizations, and improve survival in cancer patients.
advanced colorectal cancer; drug-PIN®; drug–drug–gene interaction; pharmacogenomic
01 Pubblicazione su rivista::01a Articolo in rivista
Drug–drug interactions and pharmacogenomic evaluation in colorectal cancer patients. The new drug-pin® system comprehensive approach / Roberto, M.; Rossi, A.; Panebianco, M.; Pomes, L. M.; Arrivi, G.; Ierino, D.; Simmaco, M.; Marchetti, P.; Mazzuca, F.. - In: PHARMACEUTICALS. - ISSN 1424-8247. - 14:1(2021), pp. 1-12. [10.3390/ph14010067]
File allegati a questo prodotto
File Dimensione Formato  
Roberto_Drug-Drug-interactions_2021.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 1.08 MB
Formato Adobe PDF
1.08 MB Adobe PDF Visualizza/Apri PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1500529
Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus 6
  • ???jsp.display-item.citation.isi??? 6
social impact